Daijiworld Media Network - Mumbai
Mumbai, Mar 22: New research has identified a previously underexplored immune signalling pathway that could help explain persistent inflammation in Atopic Dermatitis (AD), offering fresh insights into potential treatment strategies.
Atopic dermatitis is a chronic inflammatory skin disorder driven by immune imbalance, particularly involving T helper cell subsets such as Th2 and Th9. While lipid mediators have long been suspected to influence immune responses, their exact role in the disease has remained unclear.
Recent findings highlight the role of Sphingosine-1-phosphate (S1P) signalling as a key contributor to disease activity. Researchers analysed immune cells from patients with AD and healthy individuals, identifying significant differences in genes linked to lipid-mediated pathways, especially the receptor S1PR5.
Functional studies revealed that exposure to S1P increased the production of key inflammatory cytokines such as Interleukin-13 (IL-13) and Interleukin-9 (IL-9), which are central to Th2 and Th9 immune responses. Patients with atopic dermatitis were also found to have higher circulating levels of S1P, pointing to a systemic component of immune dysregulation.
Further analysis showed a contrasting role of receptors: S1PR1 was found to enhance cytokine production, while S1PR5 appeared to suppress it. This imbalance between receptor pathways may contribute to the excessive inflammation seen in AD.
Researchers noted that the findings shed light on how disrupted lipid signalling can drive immune imbalance in the condition, potentially opening the door for targeted therapies aimed at modulating S1P receptor activity.
However, the study was based on laboratory experiments, and experts emphasised the need for clinical validation to determine whether these findings can translate into effective treatments.
The research marks a step forward in understanding the complex immune mechanisms behind atopic dermatitis and highlights a promising new avenue for therapeutic intervention.